Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 535 for:    VANCOMYCIN

Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion (VANCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04017468
Recruitment Status : Recruiting
First Posted : July 12, 2019
Last Update Posted : November 5, 2019
Sponsor:
Collaborator:
University Hospital Freiburg
Information provided by (Responsible Party):
University Hospital Inselspital, Berne

Brief Summary:
Surgical site infections (SSI) after spine surgery may occur in up to 12% of cases and can lead to increased morbidity, and healthcare costs In this randomized controlled trial the investigators aim to prospectively investigate the efficacy and safety of suprafascial intrawound vancomycin powder in reducing the rate of SSIs after instrumented spinal fusion surgery. Secondary aims of the study are the incidence of vancomycin-related complications, vancomycin-resistant bacterial infections in the treatment arm as well as the rate of revision surgeries due to SSIs.

Condition or disease Intervention/treatment Phase
Surgical Site Infection Drug: Vancomycin Phase 2

Detailed Description:

Background:

Surgical site infections (SSI) after spine surgery may occur in up to 12% of cases and can lead to increased morbidity, and healthcare costs. Numerous retrospective studies suggest the use of intrawound (subfascial) vancomycin powder in spine surgery to be protective against SSIs. Adverse events, such as seroma formation or neurotoxicity may be associated with the subfascial use of vancomycin powder in high doses in direct proximity to exposed neural structures. Only one retrospective study investigated the use of suprafascial vancomycin powder. The use of intrawound vancomycin powder is controversial and there is a paucity of well-designed prospective trials evaluating its efficacy and safety in spine surgery.

Objective:

The main objective of this Trial is to evaluate the efficacy and safety of suprafascially applied vancomycin powder in open instrumented spine surgery to prevent surgical site infections and inform a future phase-III trial.

Methods:

In addition to standard preoperative systemic antibiotic prophylaxis (SAP), patients in the treatment arm will receive 1-2 g of vancomycin powder (VP) applied above the closed muscle fascia (suprafascial) into the wound at conclusion of the surgery. Patients in the control arm will not receive additional intrawound vancomycin powder. All other intra- and perioperative procedures will be conducted according to standard of practice (SOP) at the respective Trial site. All patient follow-ups and assessment of the surgical site will be observational in nature and adhere to Standard Operating Procedure (SOP) of the Trial site. All patients will be followed up clinically with conventional radiographs after 6 weeks and 3 months after surgery. At each follow-up, clinical assessment and inspection of the surgical site (the wound) will be performed by a blinded assessor (who was not present at index surgery). In cases of evident or suspected SSI standard blood samples and - if required to rule out or confirm a deep SSI - a MRI will be ordered.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion
Actual Study Start Date : October 15, 2019
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : March 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Treatment Arm
The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
Drug: Vancomycin
Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.

No Intervention: Control Arm
The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.



Primary Outcome Measures :
  1. Rate of superficial and deep SSIs (according to CDC criteria) [ Time Frame: within 90 days following index surgery ]

Secondary Outcome Measures :
  1. Rate of revision surgery due to SSIs [ Time Frame: within 90 days following index surgery ]
  2. Rate of vancomycin-resistant bacterial infections in the treatment group [ Time Frame: within 90 days following index surgery ]
  3. Rate of vancomycin-related adverse events both locally and systemically [ Time Frame: within 90 days following index surgery ]
  4. Rate of wound healing disorders without SSI within [ Time Frame: within 90 days following index surgery ]
  5. Rate of wound seromas [ Time Frame: within 90 days following index surgery ]
  6. numeric rating scale (NRS) to assess pain intensity self-reported by the patient (Score 0-10 with 0 representing no pain, and 10 maximum pain intensity) at Visits 3, 4, 5 and 6 for neck or back pain depending on surgical level (cervical or lumbosacral) [ Time Frame: day 4, day 5, day 42, day 90 ]
  7. numeric rating scale (NRS) to assess pain intensity self-reported by the patient (Score 0-10 with 0 representing no pain, and 10 maximum pain intensity) at Visits 3, 4, 5 and 6 for leg or arm pain (cervical or lumbosacral) [ Time Frame: day 4, day 5, day 42, day 90 ]
  8. Quality of life (EuroQoL 5D-5L), Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/ Depression (rating from no problems to extreme problems) and health status self rating by patient (Score 0-100, 0 the worst health and 100 the best health) [ Time Frame: day 42 and day 90 ]
  9. Length of hospital stay [ Time Frame: within 90 days following index surgery ]
  10. Cost of treatment for cost analysis between both treatment arms [ Time Frame: 1 year after index surgery ]
  11. Rate of bony fusion at the level of index surgery as assessed by CT [ Time Frame: 1 year after index surgery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients ≥ 18 years of age requiring open instrumented dorsal spinal fusion of at least 1 level (involving two adjacent vertebras and one intervertebral disc)
  • Signed informed consent

Exclusion Criteria:

  • Preoperative ongoing infectious disease present as judged by primary surgeon (based on lab results and clinical assessment);
  • Previous spine surgery at index level within last 90 days;
  • Known allergy to vancomycin;
  • Percutaneous or transmuscular instrumentation (minimally-invasive surgery) only without lumbar interbody fusion;
  • Postoperative radiotherapy of surgical site required (e.g. for tumor)
  • Preexisting cochlea damage OR known history of hearing loss;
  • Renal insufficiency with stage 4 chronic kidney disease (CKD) with a glomerular filtration rate (GFR) of 15-30 ml/min or worse;
  • Pregnancy or breastfeeding women;
  • Participation in other ongoing clinical trials;
  • Patients lacking capacity to consent;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04017468


Contacts
Layout table for location contacts
Contact: Ralph Schaer, MD +413120014 ralph.schaer@insel.ch
Contact: Nicole Soell +41316323164 Nicole.Soell@insel.ch

Locations
Layout table for location information
Switzerland
University Hostpital Bern, Department of Neurosurgery Recruiting
Bern, Switzerland, 3010
Contact: Ralph Schaer, MD    +413120014    ralph.schaer@insel.ch   
Contact: Nicole Soell    +413123164    nicole.soell@insel.ch   
Sponsors and Collaborators
University Hospital Inselspital, Berne
University Hospital Freiburg
Investigators
Layout table for investigator information
Principal Investigator: Schaer Ralph, MD Inselspital Bern, Department of Neurosurgery

Layout table for additonal information
Responsible Party: University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier: NCT04017468     History of Changes
Other Study ID Numbers: 2019-01143
First Posted: July 12, 2019    Key Record Dates
Last Update Posted: November 5, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Surgical Wound Infection
Wound Infection
Postoperative Complications
Pathologic Processes
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents